New York, USA - October 27, 2022 - CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis and design to the science community, recently announced the establishment of a Glycosylation Site-specific ADC Development Platform to help its global clients in this field.
Antibody-Drug Conjugates (ADCs) link the cytotoxin to the antibody through chemical linker, and use the targeting effect of the antibody to achieve the specific killing of the toxin on the tumor. ADC compounds obtained by site-specific coupling technology have better therapeutic index than random coupling, which is one of the current research hotspots in the field of ADC.
Fc domain N297 is a conserved glycosylation site of antibodies, and the introduction of glycosite-specific ADCs (gsADCs) formed by cytotoxins at this site has the advantages of no effect on antigen binding and better stability, which has received much attention in recent years. At present, the reported glycosite-specific coupling strategy first requires glycoengineering modification of antibodies, introduction of bioorthogonal groups at the glycosylation site by glycosyltransferases or glycoside endonucleases, and further conjugation of toxins through bioorthogonal reactions, so as to achieve the preparation of glycosite-specific ADCs.
Now, at CD BioGlyco, three glycosylation site-specific conjugation strategies to bind payloads are available, including: glycan oxidation, glycan enzymatic modification and glycoengineering.
Glycan Oxidation-based ADC Development
Scientists at CD BioGlyco use the periodate oxidation process to convert the sugar group in the antibody's native glycan to an aldehyde group, which is subsequently coupled with a small molecule hydrazide or aminooxy chemical.
Glycan Enzymatic Modification-based ADC Development
Enzymatic transfer of galactose and sialic acid, enzymatic transfer of galactose and 9-azidosialic acid, and enzymatic removal of terminal galactose are three enzymatic techniques utilized to generate ADC at CD BioGlyco.
Glycoengineering-based ADC Development
CD BioGlyco creates ADCs by metabolically incorporating 6-thiofucose followed by conjugation with maleimide, in addition to engineering antibody glycans using in vitro chemical and enzymatic modification techniques.
"Our unrivaled competence in the design and analysis of glycobiology and other studies will assist you decrease time and expense for the drug development process." Commented Anna, one of the representative speakers from CD BioGlyco.
To know more detailed information about the Glycosylation Site-specific ADC Development Platform newly released at CD BioGlyco, please visit https://www.bioglyco.com/glycosylation-site-specific-antibody-drug-conjugate-adc-development-platform.html.
Media Contact
Company Name: CD BioGlyco
Contact Person: Anna
Email: Send Email
Phone: 1-631-749-6145
Country: United States
Website: https://www.bioglyco.com
